Citadel Advisors
NGNE icon

Citadel Advisors’s Neurogene NGNE Stock Holding History

Citadel Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$304K Buy
+15,100
New +$292K ﹤0.01% 10437
2025
Q2 		– Sell
-40,600
Closed -$475K – 14198
2025
Q1 		$475K Buy
40,600
+9,400
+30% +$163K ﹤0.01% 8585
2024
Q4 		$713K Buy
+31,200
New +$1.16M ﹤0.01% 7790
2023
Q4 		– Sell
-890
Closed -$14.1K – 14906
2023
Q3 		$14.1K Buy
890
+655
+279% +$9.67K ﹤0.01% 12896
2023
Q2 		$3.9K Sell
235
-455
-66% -$7.46K ﹤0.01% 13646
2023
Q1 		$9.66K Buy
+690
New +$8.09K ﹤0.01% 13577
2022
Q3 		– Sell
-3,445
Closed -$71K – 13261
2022
Q2 		$71K Sell
3,445
-220
-6% -$5.37K ﹤0.01% 11694
2022
Q1 		$138K Sell
3,665
-515
-12% -$30K ﹤0.01% 11944
2021
Q4 		$403K Buy
+4,180
New +$509K ﹤0.01% 10198
2021
Q3 		– Sell
-1,945
Closed -$359K – 14369
2021
Q2 		$359K Sell
1,945
-105
-5% -$23.2K ﹤0.01% 10832
2021
Q1 		$505K Buy
2,050
+80
+4% +$20.4K ﹤0.01% 9659
2020
Q4 		$556K Buy
+1,970
New +$481K ﹤0.01% 7944
2020
Q3 		– Sell
-830
Closed -$276K – 10513
2020
Q2 		$276K Sell
830
-80
-9% -$20.9K ﹤0.01% 8044
2020
Q1 		$207K Buy
+910
New +$187K ﹤0.01% 7955
2018
Q4 		– Sell
-1,205
Closed -$71K – 9551
2018
Q3 		$71K Sell
1,205
-3,645
-75% -$215K ﹤0.01% 8705
2018
Q2 		$257K Buy
4,850
+4,245
+702% +$1.11M ﹤0.01% 7479
2018
Q1 		$170K Buy
+605
New +$167K ﹤0.01% 7457

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Citadel Advisors's NGNE Position: Q1 2026 in Review

Citadel Advisors increased its Neurogene (NGNE) stake by 6.3% in Q1 2026, buying an estimated $442K and bringing the position to 387,031 shares worth $7.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3616.

Citadel Advisors first reported a position in NGNE in Q3 2017 and has held it in 21 quarters since. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Citadel Advisors held 387,031 shares of Neurogene worth $7.8M as of Q1 2026.
  • Citadel Advisors bought 22,803 Neurogene shares in Q1 2026, an estimated $442K.
  • Neurogene made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3616 holding.
  • Citadel Advisors first reported a position in Neurogene in Q3 2017 and has held it in 21 quarters since.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.